Market revenue in 2023 | USD 217.4 million |
Market revenue in 2030 | USD 542.5 million |
Growth rate | 14% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.14% in 2023. Horizon Databook has segmented the Mexico upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico’s upstream bioprocessing market is expected to witness a lucrative growth rate during the forecast period. Mexico offers several competitive advantages in biopharmaceutical manufacturing. Its large population, low manufacturing costs, relatively relaxed regulatory framework, and strategic position as a hub for several U.S. companies are boosting biopharmaceutical growth in this region.
This growth further strengthens upstream bioprocesses involved during biomanufacturing. Most companies operating in Mexico’s biopharmaceutical industry involve subsidiaries of international companies, which are engaged in research or production processes.
Some of the biopharmaceutical firms undertake partnership and agreement models to supply their products. For instance, in January 2020, Zhittya Genesis Medicine, Inc. and Regenerative Medicine of Latin America, Inc. entered into a partnership agreement to commercialize biological drugs in the territories of Mexico.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico upstream bioprocessing market , including forecasts for subscribers. This country databook contains high-level insights into Mexico upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account